for the Brugada Syndrome Investigators in Japan Background-The prognosis of patients with saddleback or noncoved type (non-type 1) ST-elevation in Brugada syndrome is unknown. The purpose of this study was to clarify the long-term prognosis of probands with non-type 1 ECG and those with coved (type 1) Brugada-pattern ECG. Methods and Results-A total of 330 (123 symptomatic, 207 asymptomatic) probands with a coved or saddleback ST-elevation Ն1 mm in leads V 1 -V 3 were divided into 2 ECG groups-type 1 (245 probands) and non-type 1 (85 probands)-and were prospectively followed for 48.7Ϯ15.0 months. The absence of type 1 ECG was confirmed by drug provocation test and multiple recordings. The ratio of individuals with a family history of sudden cardiac death (14%) was lower than previous studies. Clinical profiles and outcomes were not notably different between the 2 groups (annual arrhythmic event rate of probands with ventricular fibrillation; type 1: 10.2%, non-type 1: 10.6%, probands with syncope; type 1: 0.6%, non-type 1: 1.2%, and asymptomatic probands; type 1: 0.5%, non-type 1: 0%). Family history of sudden cardiac death at age Ͻ45 years and coexistence of inferolateral early repolarization with Brugada-pattern ECG were independent predictors of fatal arrhythmic events (hazard ratio, 3.28; 95% confidence interval, 1.42 to 7.60; Pϭ0.005; hazard ratio, 2.66; 95% confidence interval, 1.06 to 6.71; Pϭ0.03, respectively, by multivariate analysis), although spontaneous type 1 ECG and ventricular fibrillation inducibility by electrophysiological study were not reliable parameters. Conclusions-The long-term prognosis of probands in non-type 1 group was similar to that of type 1 group. Family history of sudden cardiac death and the presence of early repolarization were predictors of poor outcome in this study, which included only probands with Brugada-pattern ST-elevation. (Circ Arrhythmia Electrophysiol. 2009;2:495-503.)
B rugada syndrome is a hereditary arrhythmogenic disease characterized by ST-elevation in the right precordial lead of standard ECGs and an increased risk of sudden cardiac death (SCD). 1 The prognosis for this condition and the management approaches have been reported in several multicenter studies of patients with the coved type 1 ECG. However, no prospective data have been reported in patients with saddleback type or noncoved Brugada-pattern STelevation before, because they were excluded from previous Clinical Perspective on p 503 studies as atypical Brugada patients showing a benign clinical course. Besides, the data from previous studies are all conflicting with regard to the prognosis of the typical Bru-gada syndrome. [2] [3] [4] [5] This may be caused by cohort studies that included a significant number of family members other than probands, in which the prognosis of pedigree members can be affected by the disease severity of probands. Furthermore, a selection bias can be present if the data are analyzed retrospectively. Therefore, we aimed to investigate the long-term prognosis of probands with noncoved type ST-elevation in leads V 1 -V 3 , prospectively, and compared it with that of probands with the type 1 ST-elevation.
Methods

Patient Population
A total of 330 individuals with spontaneous ST-elevation were registered consecutively in this study, namely, "a multicenter study for risk stratification and management in patients with Brugada syndrome." The study was conducted at 26 institutions across Japan beginning in July 2001. These individuals were prospectively followed up for more than 12 months to the end of March 2007. Subjects were enrolled in this study if they met the following inclusion criteria: (1) proband, (2) J-point (QRS-ST junction) amplitude of Ն0.1 mV (1 mm) with either coved or saddle back type ST-segment elevation in at least 2 of the 3 precordial leads (V 1 -V 3 ) on resting standard 12-lead ECG, (3) normal findings on physical examination, and (4) no abnormality in either right or left ventricular morphology and/or function demonstrated by chest radiography and echocardiography. Patients with vasospastic angina and those with vasovagal syncope were excluded from this study. Patients were not administered antiarrhythmic drugs and did not have electrolyte abnormalities at the time of baseline ECG recording and other examinations.
Classification of Groups
We divided the 330 patients with Brugada-pattern ECG into 3 groups according to their symptoms: The ventricular fibrillation (VF) group consisted of 56 probands with aborted sudden death and/or documented VF, the syncope group consisted of 67 probands with syncope without documented arrhythmias that was not typical for vasovagal syncope, and the asymptomatic group consisted of 207 asymptomatic individuals whose ECGs were mainly detected by individual annual medical checkup or health screening in their place of employment.
We also divided these patients into 2 groups according to ECG morphology: The type 1 group consisted of 245 probands with a spontaneous type 1 ECG or those who developed type 1 ECG with a drug provocation test. The non-type 1 group consisted of the remaining 85 probands who never showed type 1 ST-elevation even with the drug provocation test ( Figure 1 ) and during the follow-up on standard 12-lead ECGs.
Clinical Data, ECG, and Electrophysiological Testing
Clinical data including age at the enrollment, sex, family history of SCD, and the presence of atrial fibrillation were collected for all patients. The standard ECGs were recorded more than 5 times during the follow-up period in all patients. ECG recording on higher intercostals spaces (third and/or second) in leads V 1 -V 3 6 was encouraged in patients who had cardiac events during the follow-up period.
A type 1 ECG was defined as a prominent coved ST-segment elevation displaying J-point wave amplitude or ST-segment elevation Ն2 mm or 0.2 mV. 7, 8 ECG patterns with a prominent coved ST-elevation Ն2 mm followed by a positive or flat T wave were also included in type 1 group (Figure 2A through C). A non-type 1 ECG was defined as one of the following: type 2 ECG, 7 type 3 ECG, 7 and ECG displaying coved or saddleback ST-elevation with J-wave amplitude Ն1 mm and Ͻ2 mm (Figures 1 and 2D through 2G).
The presence of early repolarization in the inferolateral leads 9 was evaluated by baseline 12-lead ECGs at the time of enrollment to elucidate ECG findings associated with Brugada syndrome. Early repolarization was defined as an elevation of the J point in at least 2 leads. The amplitude of the J wave or J-point elevation had to be at least 1 mm above the baseline level, either as QRS slurring or notching in the inferior lead (II, III, and aVF), lateral (I, aVL, and V 4 -V 6 ) lead, or both. 9 ECGs were evaluated by 3 independent investigators (S.K., N.A., and W.S.) who were unaware of the patients' other clinical information. The ECG type or morphology was established by the evaluation in which at least 2 of the 3 observers were in agreement.
Sodium channel blocker pilsicainide (1 mg/kg body weight at a rate of 5 to 10 mg/min), disopyramide (1.5 mg/kg, 10 mg/min), flecainide (2 mg/kg, 10 mg/min), or procainamide (10 mg/kg, 100 mg/min) was administered intravenously in 270 (82%) patients (233, 15, 14, and 8, respectively) to test the conversion to typical coved ST-elevation. 8, 10, 11 Baseline electrophysiological studies (EPS) were performed in 232 (70%) patients. A maximum of 3 ventricular extrastimuli were delivered from 2 right ventricular (RV) sites (RV apex and RV outflow tract) unless VF or polymorphic ventricular tachycardia (VT) (lasting Ն10 beats) that terminated spontaneously within 30 seconds, causing syncope, or requiring intervention to be terminated was elicited at a previous step. Premature beats were started in late diastole; coupling intervals were then reduced in 10-ms decrements until refractoriness was reached. Stimulation was performed at twice the diastolic threshold. Patients with inducible ventricular arrhythmias lasting less than 10 beats were classified as noninducible. The indices including age, sex distribution, a family history of SCD at Figure 1 . Presentation of 12-lead ECGs of a patient with non-type 1 ST-elevation. A, Baseline 12-lead ECG; B, 12-lead ECG after provocation by intravenous administration of 50 mg pilsicainide in the same patient. Saddlebacktype ST-elevation in leads V 1 and V 2 was enhanced after pilsicainide but was not changed to type 1 ST-elevation. This 46-yearold male patient with a history of syncope but with no family history of SCD had inducible VF by electrophysiological study. He had spontaneous VF 11 months after enrollment. less than 45 years of age, and VF/polymorphic VT inducibility were compared with those reported in previously published studies 2,3,5 ( Table 1 ). In addition to these parameters, the presence of atrial fibrillation, cardiac events at night, and inferolateral early repolarization were compared between type 1 and non-type 1 groups.
Patient treatment was based on clinical judgment of the participating hospital. Twenty-eight (8%) probands received antiarrhythmic drugs (quinidine sulfate Յ400 mg, bepridil Յ200 mg, disopyramide Յ300 mg, aprindine Յ30 mg, and amiodarone Յ200 mg/d) for prevention of atrial fibrillation or VF. Calcium antagonists were administered in 18 (5%) probands for hypertension. Quinidine and bepridil were administered only after a documentation of VF during follow-up. Among the 330 patients, 125 (38%) received an implantable cardioverter-defibrillator (ICD). During follow-up, patients were considered to have an arrhythmic event if sudden death occurred or VF was documented.
Statistical Analysis
Data are presented as meanϮstandard deviation. The Fisher exact test or the 2 test was used for categorical variables. One-way ANOVA was used for comparisons of continuous variables among the different groups. Survival curves were plotted by the Kaplan-Meier method and analyzed by the log-rank test. Cox proportional hazards models were used to analyze factors associated with the time to the first arrhythmic event during follow-up in all probands as well as in type 1, non-type 1, VF, and non-VF (syncope and asymptomatic) groups. Variables were included in the multivariate analysis with the use of a forward stepwise procedure with a criteria of PϽ0.05 for inclusion and PϾ0. 15 for removal from the model. A probability value of PϽ0.05 was considered statistically significant.
This study was performed under the ethical code approved by the Health, Labor, and Welfare Ministry of Japan. Written informed consent was obtained from all individuals.
Results
Clinical Profiles of All Probands
The mean age of the 330 probands was 51.4Ϯ14.8 years (median, 53 years; range, 4 to 86 years). The majority (315; 95%) of probands were male. A low percentage (14%) of patients had a family history of SCD occurring before the age of 45 years. The induction rate of VF/polymorphic VT by EPS was higher (77/109: 72%, PϽ0.005) in symptomatic than asymptomatic probands (61/123: 50%) ( Table 1 ).
Comparison of Clinical Characteristics Between Type 1 and Non-Type 1 Groups
Type 1 ECG was found in 245 probands (VF group: 45, 18%; syncope group: 46, 19%; and asymptomatic group: 154, 63%). Of these 245 probands, 173 (71%) showed type 1 ECG spontaneously and the remaining 72 (29%) showed characteristic type 1 morphology after class Ic or Ia antiarrhythmic drug administration. In 85 probands of the non-type 1 group (VF group: 11, 13%; syncope group: 21, 25%; and asymptomatic group: 53, 62%), non-type 1 ECG remained during the drug provocation test (type 2: 61, 72%; coved with J-point amplitude Ͻ2 mm: 24, 28%) and the follow-up period. Most of the clinical parameters except for VF/VT inducibility, namely, age, sex distribution, the prevalence of atrial fibrillation, the presence of a family history of SCD, cardiac events at night (8 PM to 8 AM), and early repolarization, were of similar occurrence between type 1 and non-type 1 groups (Table 2 ). Only 8% (7/85) of probands in the non-type 1 group and 11% (26/245) of those in the type 1 group were associated with early repolarization in the inferolateral leads.
Follow-Up and Predictors of Outcome
The mean follow-up period for the entire study population was 48.7Ϯ14.9 months. Follow-up time was similar among VF (51.9Ϯ15.0 months), syncope (48.5Ϯ14.0 months), and asymptomatic (47.7Ϯ15.0 months) groups and between type 1 (48.6Ϯ15.2 months) and non-type 1 (48.9Ϯ14.2 months) groups. Twenty-four patients had fatal arrhythmic events during follow-up. The frequency of events in the type 1 group-15 of 45 (33%) in patients with VF, 1 of 46 (2%) in syncope patients, and 3 of 154 (2%) in asymptomatic patients-was similar to that in the non-type 1 group (4/11: 36%, 1/21: 5%, and 0/53: 0%, respectively, Pϭ0.22; Figure 3 ). In 5 patients who had events in the non-type 1 group, 2 had shown a type 1 ST-elevation only in the higher (second or third) intercostal spaces-1 in a follow-up ECG and 1 after drug provocation test. The observed frequency of arrhythmic events was significantly highly in patients with early repolarization in the inferolateral leads (7/33; 21% versus 17/297; 6%, PϽ0.005), although there was no difference in risk between the 2 groups (type 1: 6/26; 23%, non-type 1: 1/7; 14%, Pϭ0.67). One asymptomatic patient with type 1 ECG died suddenly 3 months after enrollment. Six patients died of nonarrhythmic causes; 3 died of cancer, 1 because of rupture of abdominal aortic aneurysm, 1 because of pneumonia, and cause of death for 1 patient was unknown. Seven percent of all patients who entered the study dropped out, the most frequent reason for drop-out was inability of follow-up due to patient's change of address. Figure 4 shows the Kaplan-Meier analysis of arrhythmic events in probands with type 1 and non-type 1 ECG. Probands in the VF group had significantly worse prognosis than those in the syncope and asymptomatic groups. The annual rate of arrhythmic events in probands with type 1 ECG was 10.2% in the VF group, 0.6% in the syncope group, and 0.5% in the asymptomatic group ( Figure 4A ). The cumulative rate of arrhythmic events in probands with non-type 1 ECG was similar to those with type 1 ECG. The annual arrhythmic event rate was 10.6%, 1.2%, and 0%, respectively ( Figure 4B ).
By univariate analysis, a family history of SCD was a predictor for arrhythmic events in the type 1 group (hazard ratio [HR], 5.1; 95% CI, 2.0 to 12.8; Pϭ0.0004) and the non-type 1 group (HR, 12.3; 95% CI, 2.0 to 74.8; Pϭ0.006). Coexistence of posterolateral early repolarization with precordial Brugada-pattern ECG was another predictor in the type 1 group (HR, 4.2; 95% CI, 1.6 to 11.2; Pϭ0.003); however, other parameters were not reliable. Figure 5 shows the Kaplan-Meier curves of arrhythmic events in the type 1 group during follow-up, depending on the presence of a family history of SCD ( Figure 5A ), inferolateral early repolarization ( Figure 5B ), a spontaneous type 1 ST-elevation ( Figure 5C ), and inducibility of ventricular arrhythmias by EPS ( Figure 5D ). Multivariate analysis in all probands identified that the former 2 parameters were independent risk factors for arrhythmic events (a family history of SCD: HR, 3.28; 95% CI, 1.42 to 7.60; Pϭ0.005; early repolarization: HR, 2.66; 95% CI, 1.06 to 6.71; Pϭ0.03, Table 3 ) as well as a family history of SCD in analysis of probands without VF (syncope and asymptomatic groups) (HR, 12.5; 95% CI, 2.0 to 75.0; Pϭ0.005).
Discussion
Main Findings
We present one of the largest series of consecutive patients with Brugada-pattern ECG. Importantly, in the present study only probands were included. Also, this study has the longest follow-up ever reported. The main finding is that probands who have a non-type 1 ECG, even after challenged with a sodium channel blocker, do not necessarily have a better prognosis than patients with spontaneous or drug-induced type 1 ECG. Patients presenting with aborted cardiac arrest had a grim prognosis and those presenting with syncope or no symptoms had an excellent prognosis irrespective of their ECG pattern (that is, type 1 versus non-type 1). Also, a family history of sudden death at age Ͻ45 years and coexistence of early repolarization in the inferolateral leads were predictors of poor outcome. In contrast, VF/VT inducibility during EPS was not a predictor of outcome.
Comparison With Previous Studies
In this study, the follow-up time was uniform among the 3 groups. The mean follow-up time for the asymptomatic individuals was the longest (47.7Ϯ15.0 months) compared with the studies by Brugada et al 2 (27Ϯ29 months), Priori et al 3 (34Ϯ44 months), and Eckardt et al 5 (33.7Ϯ52.2 months). The percentage of female patients (5%) and patients with a family history of SCD (14%) was significantly smaller than 2 of these previous reports (5% versus 24% to 28% 2,3,5 ; PϽ0.001, and 14% versus 28% to 54% 2,3,5 ; PϽ0.001), although the percentage (14%) of a family history of SCD was similar to that of probands (20%) that Priori et al 3 had reported. The values observed in the present study may reflect the true profile of the probands of Brugada syndrome in contrast to previous studies in which a significant number of family members were also enrolled.
Prognosis of Probands Presenting With Syncope and Without Symptoms
The prognosis of probands in the syncope and asymptomatic groups was very good, and the annual rate of arrhythmic events was Յ1.2%. In the syncope group, this rate is far less than reported in previous studies, 2 rate in the asymptomatic group is similar to that in the Eckardt registry 5 and the rate of around 10% for the VF group is comparable to the rate reported in the Brugada registries. 2, 8 The reason that the patients in the syncope group showed excellent prognosis is not entirely clear but may be related to the method of registry. Poor prognosis in prior studies is possibly related to the retrospective design of the studies consisting of probands and family members, 2, 3, 5 in which only severe syncope directly linked to VF tends to be categorized later as a syncope, despite difficulty to determine the cause of syncope at the onset. Even so, we cannot exclude the possibility that some patients with vasovagal syncope were inevitably included in the syncope group because not a few patients have undefined syncope and Ͼ30% of Brugada patients are reported to have both vasovagal syncope and the syncope due to ventricular arrhythmia. 12 Another reason for the good prognosis is the difference of genetic background. Brugada syndrome is known to be common in Asian people, which possibly relates to the higher prevalence of polymorphism of haplotype B, associated with the cardiac sodium channel. 13, 14 The average prognosis of Asian patients with Brugada syndrome may be better than that of the white population, because individuals without a critical genetic defect are easily detected as a Brugada patient in a routine medical checkup. Further genetic studies are required to clarify the racial difference of outcome. Nevertheless, the patients in this study with an aborted sudden death showed worse prognosis than European people in the study by Eckardt et al 5 and had a similar outcome to those who underwent ICD implantation. 15
Prognosis of Probands With Non-Type 1 ECG
The outcome of probands with non-type 1 ECG was similar to those with type 1 ECG and the rate of arrhythmic events in the VF group was considerably higher. Some of these patients had shown a coved (type 1) ST-elevation only in the higher (second or third) intercostal spaces during the drug provocation test or follow-up. Miyamoto et al 16 recorded only at the higher leads V 1 and V 2 showed a prognosis similar to that of men with a type 1 ECG when using standard leads. In the past, patients with non-type 1 ST-elevation in standard ECG had been excluded from studies as a benign entity of Brugada syndrome. However, if patients had a history of aborted sudden death or agonizing nocturnal dyspnea, non-type 1 Brugada-pattern ECG should not be disregarded. Careful follow-up including ECG recording at the higher intercostals spaces and the implantation of ICD is probably required in such a patient to prevent SCD.
Clinical Features of Probands With Non-Type 1 ECG
The clinical profiles of probands were very similar between the non-type 1 group and the type 1 group (Table 2) . Inferolateral early repolarization occurred equally in small percentage of patients in both groups (8% and 11%, respectively), which is comparable to the prevalence (12%) of early repolarization that Letsas et al 17 reported in patients with Brugada syndrome. This means that the patient characteristics of the non-type 1 group are much closer to Brugada syndrome than early repolarization syndrome reported by Haïssaguerre et al, 9 in which the VF occurrence rate during sleeping was low (19%) and VF inducibility by EPS was only 34%. Moreover, they reported that several aspects including the relapsing VF and the efficacy of isoproterenol and quinidine, 9, 18 In contrast, a family history of SCD occurring at age of Ͻ45 years is an independent risk factor of a poor prognosis in probands of any groups irrespective of their ECG type (type 1 or non-type 1) or symptoms (with VF or without VF). This was probably caused by a smaller proportion of probands with a family history of SCD as compared with previous studies 2-5 A family history was not found to be a marker in studies that enrolled many patients with SCD or a family history of Brugada syndrome. These results indicate that we should evaluate risks for arrhythmic events cautiously in studies with a significant number of family members.
Predictors of Outcome
Early repolarization pattern in the inferolateral leads was another indicator of poor prognosis, although Letsas et al 17 did not find any association with arrhythmic events in the data collected from 3 European centers, which also included Ϸ30% of patients with a family history of SCD. The reason for the poor outcome in probands with early repolarization in this study is not clear. However, it is conceivable that the combination of precordial Brugada-pattern ST-elevation with inferolateral early repolarization may represent electric heterogeneity in extensive regions of ventricles, which can result in lethal ventricular arrhythmias.
Study Limitations
In this study, premature ventricular electric stimulation was given until refractoriness was reached. The minimal coupling interval of extrastimuli was not constant between participating hospitals and was sometimes shortened to Ͻ200 ms to induce ventricular arrhythmias.
We did not show the results of genetic analysis in this report, although more than half of the patients underwent genetic screening. Detailed results will be presented in a future report. So far, no positive relationship between genetic findings and patient outcomes has been found. 3, 19 We did not record ECGs at the higher intercostals spaces systematically except for probands with cardiac events, because the importance of "high-recording" became apparent in the course of this study. 6 Therefore, some patients of the non-type 1 group may have shown type 1 ST-elevation at the higher precordial positions.
Conclusions
This study described the long-term prognosis of probands with noncoved (non-type 1) Brugada-pattern ECG compared with type 1 ECG. The annual incidence of fatal arrhythmic events was similar between the 2 groups, which reached 10.6% in probands with non-type 1 ECG and a prior episode of VF. A family history of SCD occurring at age of Ͻ45 years and the presence of early repolarization were indicators of poor outcome although VF inducibility and a spontaneous type 1 ST-elevation were not reliable indicators in this prospective study including only probands.
